Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report)‘s stock had its “sell (e+)” rating reissued by Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.
Ernexa Therapeutics Stock Up 4.6%
Shares of NASDAQ ERNA opened at $1.37 on Wednesday. The firm has a market cap of $10.51 million, a PE ratio of -0.16 and a beta of 5.62. Ernexa Therapeutics has a 12-month low of $1.09 and a 12-month high of $18.75. The company’s fifty day simple moving average is $1.39 and its 200 day simple moving average is $2.24.
Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported ($0.61) earnings per share (EPS) for the quarter.
About Ernexa Therapeutics
Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.
Recommended Stories
- Five stocks we like better than Ernexa Therapeutics
- 3 Best Fintech Stocks for a Portfolio Boost
- Lowe’s vs. Home Depot: Which Benefits More From Lower Rates?
- How is Compound Interest Calculated?
- These 5 Beaten-Down Tech Stocks Could Catch Fire Next
- What Investors Need to Know to Beat the Market
- Falcon Flex Drives Growth as CrowdStrike Bets on AI Security
Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
